LESLIE I. ROSE, M.D., F.A.C.P.; RICHARD H. UNDERWOOD, Ph.D.; STEPHEN R. NEWMARK, M.D., F.A.C.P.; ELDAD S. KISCH, M.D.; GORDON H. WILLIAMS, M.D., F.A.C.P.
Peripheral blood levels of testosterone, estradiol, luteinizing hormone, and follicle-stimulating hormone and the metabolic clearance rates of testosterone and estradiol, as well as the peripheral conversion of testosterone into estradiol, were measured in 16 patients with hypertension. Six of these patients were treated with spironolactone and developed gynecomastia. The other 10 patients served as control subjects. The blood testosterone level in the spironolactone-treated group (2.7 ± 0.5 ng/ml) was significantly less (P < 0.02) than in the control group (4.4 ± 0.4 ng/ml). On the other hand, blood estradiol levels in the spironolactone group (30 ± 4 pg/ml) were significantly greater (P < 0.01) than in the control group (13 ± 2 pg/ml). These changes were primarily due to significant increases in the metabolic clearance rate of testosterone (P < 0.02) and in the rate of peripheral conversion of testosterone into estradiol (P < 0.001) in the spironolactone-treated group. Thus, spironolactone does alter the peripheral metabolism of testosterone resulting in changes in the ratio of testosterone to estradiol, which could contribute to the production of gynecomastia.
ROSE LI, UNDERWOOD RH, NEWMARK SR, KISCH ES, WILLIAMS GH. Pathophysiology of Spironolactone-Induced Gynecomastia. Ann Intern Med. ;87:398–403. doi: 10.7326/0003-4819-87-4-398
Download citation file:
Published: Ann Intern Med. 1977;87(4):398-403.
Cardiology, Coronary Risk Factors, Hypertension, Nephrology.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use